Xgeva reduces risk of skeletal events in cancer patients with bone metastasesDrug indicated for reducing the of developing skeletal-related events in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer and other solid tumours. Prostate cancer ‘drug holiday’ to change care for recurring diseaseCHICAGO | Canadian research shows that men with prostate cancer who are treated with intermittent courses of androgen-suppressing therapy live as long as those who receive continuous therapy. New myeloablative therapy offers hope for kids with neuroblastoma Survival gains seen with busulphan and melphalan treatment Gardasil HPV vaccine approved for rectal cancer prevention HPV infection strongly associated with anal cancer. Memorial University School of Pharmacy to award its first PhD Mohamed Mahmoud's research involved new drug delivery system capable of providing more constant, sustained delivery of treatment for cancer. Ovarian tumour gene profile revealed Overexpression of certain proteins may guide chemotherapy Unintended tumour morcellation proves deadly Users of minimally invasive technique ‘hovering on the brink of safety’ Bladder cancer referrals blocked? Few Canadians getting neoadjuvant management, study shows Robot negates need for thrombosis prophylaxis Venous thromboembolism rates low after endometrial cancer surgery, suggesting heparin may be unnecessary Cetuximab fails in treating advanced cervical cancer Benefit in tumours with squamous cell histology not ruled out First Previous 50 51 52 53 54 Next Last